ResearchMoz

Humulin (Type 2 Diabetes) - Analysis and Forecasts to 2020

GlobalData
Published Date » 2012-01-31
No. Of Pages » 44


GlobalDatas pharmaceuticals report, Humulin (Type 2 Diabetes) Analysis and Forecasts to 2020 provides Humulin sales estimates for US, EU5 and Japan. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2002-2020). The report also includes information on Type 2 Diabetes market. This report is built using data and information sourced from GlobalDatas proprietary databases, primary and secondary research using Companys corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by GlobalData's team of industry experts.

Scope

  • Therapy area profile including patient population for the US, EU5 and Japan (seven major markets)
  • Analysis and review of Humulin including historical sales data
  • Qualitative and quantitative assessment of market space
  • Analysis of the trends, drivers and restraints shaping and defining the markets
  • In-depth analysis of Humulin including efficacy, safety, pricing, competition and other details which influence its sales potential
  • Detailed sales forecast for 2011-2020 for Humulin in each of the seven major markets
Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of competition by understanding the changing competitive landscape
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of the drugs performance 
  • Examine the historical sales performance of a drug in seven major markets
  • Obtain sales forecast for currently marketed/pipeline drug for 2011-2020 for all seven major markets
Table of Content

1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 4
1.2 List of Figures 4

2 Introduction 5
2.1 Diabetes 5
2.2 Epidemiology 5
2.2.1 Prevalence 5
2.2.2 Mortality 7
2.3 Etiology and Risk Factors 9
2.3.1 Obesity 9
2.3.2 Sedentary Lifestyle 9
2.3.3 Family History and Genetics 9
2.3.4 Ethnicity 9
2.3.5 Old Age 9
2.4 Economic Impact of Diabetes 9
2.5 GlobalData Report Guidance 11

3 Type 2 Diabetes: Market Characterization 12
3.1 Type 2 Diabetes Market 12
3.2 Type 2 Diabetes Market Forecasts 13
3.3 Type 2 Diabetes Market: Drivers and Restraints 14
3.3.1 Drivers 14
3.3.2 Restraints 15

4 Classification of Diabetes 16
4.1 Types of Diabetes 16
4.1.1 Type 1 Diabetes 16
4.1.2 Type 2 Diabetes 16
4.1.3 Gestational Diabetes 16
4.2 Diabetes Complications 16
4.2.1 Cardiovascular Disease 16
4.2.2 Nephropathy 17
4.2.3 Neuropathy 17
4.2.4 Amputation 17
4.2.5 Retinopathy 17
5 Evolution of Anti-Diabetic Treatments 18

6 Medications 19
6.1 Insulin 19
6.2 Oral Medications 19
6.2.1 Sulfonylureas (SUR) 19
6.2.2 Biguanides (BGDs) 20
6.2.3 Alpha-Glucosidase Inhibitors (AGI) 21
6.2.4 Meglitinides 21
6.2.5 Thiazolidinediones (TZDs) 22
6.2.6 Dipeptidyl Peptidase IV (DPP- 4) Inhibitors 23
6.2.7 Oral Combination Therapy 23
6.3 Other Injectionable Medications 24
6.3.1 Pramlintide 24
6.3.2 Exenatide 24
6.4 Market Share as per Classes in Type 2 Diabetes 24

7 Humulin 25
7.1 Introduction 25
7.2 Mechanism of Action 25
7.3 Different Variants of Humulin 25
7.4 Clinical Studies 25
7.4.1 Safety & Efficacy Study in Humalog & Humulin R 25
7.4.2 Safety & Efficacy Study in Lantus & NPH Insulin 26
7.5 Approval History of Humulin 27
7.6 Factors Affecting Sales 27
7.6.1 First in Class 27
7.6.2 Growing Insulin Market 28
7.6.3 Advantage of Insulin Analogs over Humulin 28
7.6.4 Family of Humulin Products 28
7.6.5 Co-Branding Deal with Wal-Mart 28
7.6.6 Availability as OTC 28
7.6.7 No Competition from Biosimilars 28
7.7 Drug Evaluation 29
7.7.1 Drug Risk Benefit Score 29
7.7.2 Intensity of Competition 30
7.8 Sales Estimates 30
7.8.1 Dosing 30
7.8.2 Market Penetration 30
7.8.3 Annual Cost of Therapy 31
7.8.4 Sales Projections of Humulin 32

8 Diabetes Market: Appendix 41
8.1 Market Definitions 41
8.2 List of Abberiviations 41
8.3 Research Methodology 41
8.3.1 Coverage 42
8.3.2 Secondary Research 42
8.3.3 Forecasting 42
8.3.4 Number of patients approved to take the drug 42
8.3.5 Net Penetration of Drug 43
8.3.6 Net Annual Dosing 43
8.3.7 Annual Cost of Therapy 43
8.4 Drug Sales Estimates Model 43
8.5 Contact Us 43
8.6 Disclaimer 44
8.7 Sources 44

List of Tables


Table 1: Diabetes, World, Prevalence Estimates for the age group 20-79 years (million), 2000-2030 5
Table 2: Diabetes, Top 10 Countries, by Prevalence (million), 2010 and 2030 7
Table 3: Diabetes, Top 10 Countries, Highest Health Expenditures ($bn), 2010 10
Table 4: Type 2 Diabetes, World, Major Marketed Drugs, 2010 12
Table 5: Type 2 Diabetes, World, Major Pipeline Products in Phase III 13
Table 6: Diabetes, Worldwide, Prevalence Estimates, 2010 and 2030 14
Table 7: Overweight*, Global, Prevalence Estimates in Males Aged 15 and above (%), 2005 15
Table 8: Diabetes Drugs Evolution 18
Table 9: Type 2 Diabetes Mellitus Adults 26
Table 10: Efficacy and Insulin Dosage in Type 2 Diabetes Mellitus 27
Table 11: Approval of Humulin in the US 27
Table 12: Drug Risk Benefit Score of Humulin R 29
Table 13: Drug Risk Benefit Score of Humulin N 29
Table 14: Humulin R, Annual Cost of Therapy in Type 2 Diabetes, Global, 2011 31
Table 15: Humulin N, Annual Cost of Therapy in Type 2 Diabetes, Global, 2011 31
Table 16: Humulin PreMix, Annual Cost of Therapy in Type 2 Diabetes, Global, 2011 31
Table 17: Humulin Franchise, Annual Cost of Therapy in Type 2 Diabetes, Global, 2011 31
Table 18: Humulin, Type 2 Diabetes, Global, Sales Estimates ($m), 20022020 32
Table 19: Humulin, Type 2 Diabetes, The US, Sales Estimates ($m), 20022020 33
Table 20: Humulin, Type 2 Diabetes, The UK, Sales Estimates ($m), 20022020 34
Table 21: Humulin, Type 2 Diabetes, France, Sales Estimates ($m), 20022020 35
Table 22: Humulin, Type 2 Diabetes, Germany, Sales Estimates ($m), 20022020 36
Table 23: Humulin, Type 2 Diabetes, Italy, Sales Estimates ($m), 20022020 37
Table 24: Humulin, Type 2 Diabetes, Spain, Sales Estimates ($m), 20022020 38
Table 25: Humulin, Type 2 Diabetes, Japan, Sales Estimates ($m), 20022020 39

List of Figures


Figure 1: Diabetes, World, Comparative Prevalence in Age Group 20-79 years (%), 2010 6
Figure 2: Diabetes, World, Comparative Prevalence in Age Group 20-79 years (%), 2030 6
Figure 3: Diabetes, World, Mortality, 2010 7
Figure 4: Top 10 Causes of Mortality, Worldwide, 2008 8
Figure 5: Type 2 Diabetes, Global, Market Size Forecasts ($bn), 20102020 13
Figure 6: Mechanism of Action of Sulfonylureas 19
Figure 7: Mechanism of Action of Biguanide, Thiazolidinediones, Alpha-Glucosidase Inhibitors 20
Figure 8: Mechanism of Action of Metformin and Alpha-Glucosidase Inhibitors 21
Figure 9: Mechanism of Action of Thiazolidinediones 22
Figure 10: Mechanism of Action of DPP IV Inhibitors 23
Figure 11: Type 2 Diabetes, Global, Branded Market Share By Class (%), 2010 24
Figure 12: Humulin, Type 2 Diabetes, Global, Sales Estimates ($m), 2002-2020 32
Figure 13: Humulin, Type 2 Diabetes, The US, Sales Estimates ($m), 20022020 33
Figure 14: Humulin, Type 2 Diabetes, The UK, Sales Estimates ($m), 20022020 34
Figure 15: Humulin, Type 2 Diabetes, France, Sales Estimates ($m), 20022020 35
Figure 16: Humulin, Type 2 Diabetes, Germany, Sales Estimates ($m), 20022020 36
Figure 17: Humulin, Type 2 Diabetes, Italy, Sales Estimates ($m), 20022020 37
Figure 18: Humulin, Type 2 Diabetes, Spain, Sales Estimates ($m), 20022020 38
Figure 19: Humulin, Type 2 Diabetes, Japan, Sales Estimates ($m), 2002-2020 39
Figure 20: Humulin, Diabetes, Global, Sales Distribution by Country (%), 2020 40
Figure 21: Patients Approved for the Drug 43

Upcoming Reports:

Optoelectronics Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019
By - Transparency Market Research
Optoelectronics is the science and application of electronics that use light as their source and can detect and control the various properties of light. Optoelectronics as a science is generally accepted as a branch of photonics. By definition, in addition to visible light, optoelectronics also includes light in the form of radiation such as gamma radiation, X-rays, infrared, and ultraviolet radiation. Optoelectronics is directly connected to semiconductors as it has its origins in the quantum mechanical effects of light on electronic materials, especially semiconductors, and can also be...
Poland: bicycles market
By - Williams and Marshal Strategy
This report presents a comprehensive overview of the bicycles market in Poland and its state as of January 2014. It provides detailed analysis of the industry, its dynamics and structure. The purpose of the report is to describe the state of the bicycles market in Poland, to present actual and retrospective information about the volumes and dynamics of production, imports, exports and consumption, the characteristics of the market for the period 2008-2012 and to build a forecast for the market development until 2018. In the same way, the report presents an elaborate overview of the main...
MEMS Combo Sensors Market - Global Industry Analysis, Market Size, Share, Growth, Trends And Forecast, 2013 - 2019
By - Transparency Market Research
MEMS combo (combination) sensors combine multiple sensing capabilities in a single device. These sensors are manufactured with micromanufacturing technology and have gained significant traction with device makers in recent years. These sensors combine two or more sensors, such as gyroscopes, accelerometers, magnetometer, pressure sensor and compasses, in a single device. Combo sensors can be 6-axis or 9-axis depending on the integration of sensors in the package. Combo sensor market is driven by its increased adoption in high-end smartphones and tablets in recent years. These sensors...

Research Assistance

We will be happy to help you find what you need.
Please call us or write us:

866-997-4948 (Us-Canada Toll Free)
Tel: +1-518-618-1030
Email: sales@researchmoz.com
Select License type:

Share this report

Related News

Private Schools Have Higher Male Teaching Staff Than State Schools: Report
Oct 22, 2014  
Private and state education has always been a matter of debate across the UK. A recent study has shown that when it comes to teaching employment options, the difference between state-run and private education in terms of gender balance is absolutely clear.  A report by the Independent Schools Council (ISC) shows that while women dominate both the education medium, the number of...
Abbots First Australian Renewable Energy Deal Rejected
Oct 22, 2014  
The Abbot government’s initial deal for a renewable energy plan has been immediately rejected by the clean energy industry and Labor. The negotiations are about a bipartisan agreement regarding the future of the Australian renewable energy target. The Labor party rejected the first plan as being a job-killer before it was even announced. The plan, they said, would protect solar...
Chemical Production in Europe Flatlines in First Seven Months of 2014
Oct 21, 2014  
The recently published report by European Chemical Industry Council (Cefic) shows overall chemical production in Europe has flatlined in first seven months of this year. Though the initial four months showed a positive trend, the production volumes dropped in July 2014 and in the following months as well. The contraction in output in the three consecutive months has nullified the upward trend...
Actavis to Compete for Omega Pharma
Oct 20, 2014  
Actavic Plc has declared that it will become one of the bidders for the Omega Pharma NV deal, as the United States based drug maker keeps searching for more takeovers. Actavis will be competing against Boehringer Ingelheim GmbH, Sanofi and Perrigi Co. for Omega Pharma. Actavis places themselves as a potential suitor along with quarry in a multitude of potential pharma combinations....
Sale of iPhone Fuels UKs s
Oct 20, 2014  
With the sale of Apple Inc.’s latest smartphone, consumer expenditure on electronics has registered a three-year high this September. The new iPhone 6 and iPhone 6 Plus were launched in the U.K. on September 19 and buyers from across the country raced to purchase the newest smartphone. Both these smartphones are so far the fastest selling Apple products with a sale of over 10 million...